. . "2-(1,3-THIAZOL-4-yl)-1H-benzimidazole"@en . . "Thiabendazole"@en . . "Mintezol"@en . . . . "148-79-8"@en . . . . . . . "TBDZ"@en . . . . . . . . . . . . "2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for strongyloidiasis. It has CNS side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919)"@en . . . . . "Thibenzole"@en . . "The precise mode of action of thiabendazole on the parasite is unknown, but it most likely inhibits the helminth-specific enzyme fumarate reductase."@en . . . . . . "Equizole"@en . . . . "4-(2-Benzimidazolyl)thiazole"@en . "Roundworms, hookworms, and other helminth species"@en . "Thiabendazole"@en . . . . . "TBZ"@en . . "For the treatment of strongyloidiasis (threadworm), cutaneous larva migrans (creeping eruption), visceral larva migrans, and trichinosis."@en . . "MK 360"@en . "Rapidly absorbed and peak plasma concentration is reached within 1 to 2 hours after the oral administration of a suspension. Some systemic absorption may occur from topical preparations applied to the skin."@en . "Lynn E. Applegate, Carl A. Renner, \"Preparation of high purity thiabendazole.\" U.S. Patent US5310923, issued October, 1977."@en . "approved"@en . . . "The half-life for thiabendazole in both normal and anephric patients is 1.2 hours (range 0.9 to 2 hours). The half-life for the 5-hydroxythiabendazole metabolite in both normal and anephric patients is 1.7 hours (range 1.4 to 2 hours)."@en . . "Overdosage may be associated with transient disturbances of vision and psychic alterations. The oral LD 50 is 3.6 g/kg, 3.1 g/kg and 3.8 g/kg in the mouse, rat, and rabbit respectively."@en . " "@en . . . "It is metabolized almost completely to the 5-hydroxy form which appears in the urine as glucuronide or sulfate conjugates."@en . . . . . "Tiabendazole"@en . . . .